Overview

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Treatments:
Budesonide
Mesalamine